This is the question where precision matters most, because the gap between what is genuinely curable and what is advertised as curable is wide — and patients pay for that gap.
The Honest List Is Short
Bone marrow and haematopoietic stem cell transplantation can be curative in a defined set of conditions: certain leukaemias and lymphomas, aplastic anaemia, severe sickle cell disease, thalassaemia, and a number of inherited immune deficiencies and metabolic disorders. Limbal stem cell grafting can durably restore the corneal surface after specific injuries.
It is worth being clear about what these treatments involve. Transplantation is a decades-old hospital procedure requiring conditioning chemotherapy, prolonged inpatient care, donor matching and management of graft-versus-host disease. It carries real mortality risk and is undertaken because the alternative is worse. It has almost nothing in common with an outpatient infusion marketed as regenerative medicine.
What "Cure" Actually Means in Medicine
Cure means the disease is eliminated and does not return without ongoing treatment. It is a higher bar than remission, in which disease activity is suppressed but may recur, and much higher than improvement, in which symptoms lessen while the underlying condition persists.
Most regenerative treatment, honestly described, aims at the third category. That is still worth having — less pain, better function, reduced inflammation — but calling it cure changes what a patient expects and what they will conclude when the effect fades.
Conditions Frequently Claimed but Not Cured
No provider anywhere can honestly claim that stem cells cure the following. Research in several of these areas is real and ongoing, which is a different and more modest statement.
- Type 1 and type 2 diabetes. Stem cell derived beta cell replacement is in trials for type 1 and has produced insulin independence in some participants, with immunosuppression required. It is not routine care, and for type 2 there is no cure claim with evidential support.
- Parkinson's disease. Dopaminergic cell replacement trials are underway and early results are of genuine scientific interest. No approved curative treatment exists.
- Multiple sclerosis. Autologous haematopoietic transplantation can halt disease activity in selected patients with aggressive relapsing MS — a disease-modifying effect achieved in specialist centres, not a cure delivered by infusion.
- Osteoarthritis. Treatment aims at pain and function. Cartilage is not regrown to a normal joint.
- Chronic kidney disease and autism. Neither has a curative cell therapy. Claims to the contrary should end the conversation.
Our page on what stem cells can fix in 2026 sets out the tiers these conditions fall into.
Where the Research Is Genuinely Promising
Being sceptical about cure claims is not the same as dismissing the field. Cell and gene therapy has produced approved treatments in haematology that were unthinkable two decades ago. Gene-edited approaches to sickle cell disease and thalassaemia have moved from concept to approval. Beta cell replacement in type 1 diabetes is producing results that warrant close attention.
What these share is a slow, evidenced path through trials — the opposite of the marketing that borrows their credibility.
Use the Word as a Filter
When you are comparing providers, watch for where "cure" appears. A programme that uses it for conditions in the list above has told you how it will describe your results afterwards, and how much weight to give anything else it says.
A programme that says "we expect this much improvement, measured this way, over this period, and here is what happens if it does not work" is giving you something you can act on. Our guide to choosing a stem cell clinic turns that into a set of questions to ask.
Get a Realistic Assessment, Not a Promise
Send your diagnosis and recent imaging and our medical team will tell you what treatment can and cannot be expected to change. Learn more about MRC Healthcare or arrange a consultation.
Schedule a Consultation
